Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation
- PMID: 28412319
- DOI: 10.1016/j.jstrokecerebrovasdis.2017.02.022
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation
Abstract
Background: Warfarin has a narrow therapeutic window. We hypothesized that genetic factors related to warfarin metabolism (CYP2C9) and activity (VKORC1) would show stronger associations than modifiable factors with the quality of anticoagulation control and risks for thromboembolism and hemorrhage.
Methods: In this retrospective cohort analysis, clinical and genetic data were collected from 380 patients with atrial fibrillation (AF) who were followed for an average observation period of 4 years. We evaluated the factors associated with time in therapeutic range (TTR, international normalized ratio [INR]: 2-3) and vascular events (either thromboembolic or hemorrhagic), including both genetic (CYP2C9 and VKORC1 genotype) and modifiable factors (anticoagulation service and warfarin dose assessment interval).
Results: The genotypic frequency of CYP2C9*3 (rs1057910) was 9.5% and that of VKORC1 1173C>T (rs9934438) was 16.3%. TTR showed dependence on VKORC1 polymorphism: TTR was higher in carriers of the VKORC1 1173C>T than of the VKORC1 TT genotype (61.7 ± 16.0% versus 56.7 ± 17.4%, P = .031). Multivariate testing showed that the VKORC1 genotype and anticoagulation service were independently related to labile INRs (TTR <65%). Vascular events were observed in 66 patients (18.4%) during the study period. A Cox proportional hazard model showed that the use of anticoagulation service and patients' characteristics, such as AF-thromboembolic risk (CHA2DS2-VASc score: Congestive heart failure, Hypertension, Age 75 years or older, Diabetes mellitus, previous Stroke or transient ischemic attack, Vascular disease, Age 65 to 74 years, female) and consequence (neurologic disability), but not genetic factors, were independently associated with vascular events.
Conclusions: Both genetic factor (VKORC1 genotype) and clinical efforts (anticoagulation service) influenced the quality of anticoagulation control. However, clinical events were more strongly associated with patient characteristics and clinical efforts than with genetic factors.
Keywords: Atrial fibrillation; CYP2C9; VKORC1; polymorphism; stroke; warfarin.
Copyright © 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.Int J Clin Pharmacol Ther. 2017 Feb;55(2):126-132. doi: 10.5414/CP202494. Int J Clin Pharmacol Ther. 2017. PMID: 27117036
-
Effect of gene polymorphims on the warfarin treatment at initial stage.Pharmacogenomics J. 2017 Jan;17(1):47-52. doi: 10.1038/tpj.2015.81. Epub 2015 Dec 8. Pharmacogenomics J. 2017. PMID: 26644206
-
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26. Thromb Haemost. 2012. PMID: 22534826
-
Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype.Pharmacogenomics. 2019 Apr;20(5):311-317. doi: 10.2217/pgs-2018-0189. Epub 2019 Apr 15. Pharmacogenomics. 2019. PMID: 30983536 Review.
-
Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: 10.14503/THIJ-14-4353. eCollection 2015 Feb. Tex Heart Inst J. 2015. PMID: 25873792 Free PMC article. Review.
Cited by
-
Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies.J Stroke. 2023 May;25(2):199-213. doi: 10.5853/jos.2022.03552. Epub 2023 Mar 15. J Stroke. 2023. PMID: 36916018 Free PMC article. Review.
-
Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.Eur J Clin Pharmacol. 2020 Feb;76(2):199-209. doi: 10.1007/s00228-019-02772-4. Epub 2019 Nov 12. Eur J Clin Pharmacol. 2020. PMID: 31720756
-
Assessment of the relationship between the level of patient knowledge on warfarin therapy and the quality of oral anticoagulation: A systematic review and meta-analysis.PLoS One. 2023 Aug 10;18(8):e0289836. doi: 10.1371/journal.pone.0289836. eCollection 2023. PLoS One. 2023. PMID: 37561771 Free PMC article.
-
Identification of environmental and genetic factors that influence warfarin time in therapeutic range.Genet Mol Biol. 2020 Feb 10;43(1 suppl 2):e20190025. doi: 10.1590/1678-4685-GMB-2019-0025. eCollection 2020. Genet Mol Biol. 2020. PMID: 32052826 Free PMC article.
-
A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement.BMC Cardiovasc Disord. 2022 Apr 19;22(1):183. doi: 10.1186/s12872-022-02620-x. BMC Cardiovasc Disord. 2022. PMID: 35439929 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous